Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M

Evofem Biosciences, Inc.

Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
Income from operations of $3.4M in FY2025 vs loss of $7.7M in FY2024; net income of $0.3M vs net loss of $9.0M.
Reduced total operating expenses by 38% to $16.8M, including gains from vendor settlement and royalty liability change.
Q4 2025 net sales of $9.6M (+35% YoY); operating income of $3.3M vs loss of $1.0M; net income of $2.8M vs loss of $3.0M.
Since Oct 2025: targeting 55-60% manufacturing cost reduction for PHEXX and SOLOSEC; UAE pricing certificates received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.